1. Scrip
  2. >>Business
  3. >>Deals

Oxford BioMedica CEO To Hire More People, Expects More Deals Following Gene Therapy Pact With Axovant

 
• By Sten Stovall

Britain's Oxford BioMedica has signed a $842m deal with US-based Axovant Sciences to commercialize its next generation gene therapy for Parkinson's disease.

Parkinsons
Duo Aim To Develop And Commercialize OXB-102 Using Oxford BioMedica's LentiVector Platform • Source: Shutterstock

Oxford BioMedica PLC's CEO says the $842m deal signed with US-based Axovant Sciences Ltd. to commercialize its next generation gene therapy for Parkinson’s disease was an important sign to players and investors that his British biotech can progress its own proprietary products while also forming partnerships, and that further new deals are likely to be announced in coming months.

Underscoring that optimism of growing business is Oxford BioMedica's plan to expand its workforce over the next 18 months in anticipation of further deals while meeting development plans for

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

A Short History Of MASH Deals, Culminating In GSK/Boston Pharma

 
• By Joseph Haas

Both high-profile failures and small investments that are yielding success so far characterize the dealmaking in MASH over the past 15 years or so.

BioMarin’s $270m Inozyme Buy Fits Right Into Enzyme Therapy Business

 
• By Mandy Jackson

BioMarin’s chief business officer James Sabry told Scrip that Inozyme’s enzyme replacement therapy INZ-701 aligns with the company’s existing portfolio and its areas of dealmaking focus.

Will Other Major MASH Deals Follow GSK/Boston Pharma?

 
• By Joseph Haas

GSK’s $1.2bn payout for Boston Pharma’s efimosfermin is the first billion-dollar-plus MASH deal in nearly nine years, but several other advanced MASH programs could be positioned for takeout.

AbbVie Pays $335m Up Front To Partner With ADARx On siRNA Therapeutics

 
• By Mandy Jackson

ADARx CEO Zhen Li told Scrip the collaborators will advance novel siRNA medicines, but ADARx retains its clinical-stage and many preclinical programs and remains open to more deals.

More from Business